XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue:    
Total revenue $ 82,422,000 $ 67,783,000
Operating expenses:    
Research and development 12,769,000 9,166,000
Selling and marketing 26,130,000 23,754,000
General and administrative 22,463,000 20,912,000
Intangible asset amortization 5,329,000 5,486,000
Total operating expenses 92,920,000 83,031,000
Loss from operations (10,498,000) (15,248,000)
Other income, net 2,407,000 784,000
Loss before income taxes (8,091,000) (14,464,000)
Income tax benefit 0 (3,000)
Net loss $ (8,091,000) $ (14,461,000)
Net loss per common share, basic (in USD per share) $ (0.11) $ (0.20)
Net loss per common share, diluted (in USD per share) $ (0.11) $ (0.20)
Shares used to compute net loss per common share, basic (in shares) 72,175,457 71,229,672
Shares used to compute net loss per common share, diluted (in shares) 72,175,457 71,229,672
Testing revenue    
Revenue:    
Total revenue $ 72,396,000 $ 55,980,000
Operating expenses:    
Cost of revenue 19,648,000 17,523,000
Product revenue    
Revenue:    
Total revenue 3,892,000 2,979,000
Operating expenses:    
Cost of revenue 2,162,000 1,575,000
Biopharmaceutical and other revenue    
Revenue:    
Total revenue 6,134,000 8,824,000
Operating expenses:    
Cost of revenue $ 4,419,000 $ 4,615,000